Selected research
Market Structure
Global Long-acting Retinal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Long-acting Retinal Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Long-acting Retinal Drugs include Janssen Pharmaceuticals (Johnson & Johnson), Takeda, Teva Pharmaceutical, Novartis, Merck, Bayer, Alcon Inc., AbbVie Inc. and ThromboGenics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Long-acting Retinal Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Long-acting Retinal Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Long-acting Retinal Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Long-acting Retinal Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Long-acting Retinal Drugs Segment by Company
Janssen Pharmaceuticals (Johnson & Johnson)
Takeda
Teva Pharmaceutical
Novartis
Merck
Bayer
Alcon Inc.
AbbVie Inc.
ThromboGenics
Regeneron
Oxurion NV
OncoGene Pharmaceuticals
MeiraGTx Limited
F. Hoffmann-La Roche
Bausch Health Co. Inc.
Allergan
Alimera Sciences Inc.
Long-acting Retinal Drugs Segment by Type
Chemically Synthesized Drugs
Biologics
Natural/Nutritional Supplements
Long-acting Retinal Drugs Segment by Application
Hospital
Clinic
Other
Long-acting Retinal Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Retinal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Long-acting Retinal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Retinal Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Long-acting Retinal Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Retinal Drugs industry.
Chapter 3: Detailed analysis of Long-acting Retinal Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting Retinal Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chemically Synthesized Drugs
- Biologics
- Natural/Nutritional Supplements
Applications
- Hospital
- Clinic
- Other
Companies covered
- Janssen Pharmaceuticals (Johnson & Johnson)
- Takeda
- Teva Pharmaceutical
- Novartis
- Merck
- Bayer
- Alcon Inc.
- AbbVie Inc.
- ThromboGenics
- Regeneron
- Oxurion NV
- OncoGene Pharmaceuticals
- MeiraGTx Limited
- F. Hoffmann-La Roche
- Bausch Health Co. Inc.
- Allergan
- Alimera Sciences Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Long-acting Retinal Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Chemically Synthesized Drugs
- 1.2.3 Biologics
- 1.2.4 Natural/Nutritional Supplements
- 1.3 Market Analysis by Application
- 1.3.1 Global Long-acting Retinal Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Long-acting Retinal Drugs Growth Trends by Region
- 1.5.1 Global Long-acting Retinal Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Long-acting Retinal Drugs Market Size by Region (2021-2026)
- 1.5.3 Long-acting Retinal Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Long-acting Retinal Drugs Market Dynamics
- 2.1 Long-acting Retinal Drugs Industry Trends
- 2.2 Long-acting Retinal Drugs Industry Drivers
- 2.3 Long-acting Retinal Drugs Industry Opportunities and Challenges
- 2.4 Long-acting Retinal Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Long-acting Retinal Drugs Revenue by Company (2021-2026)
- 3.2 Global Long-acting Retinal Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Long-acting Retinal Drugs Key Company Head office and Area Served
- 3.4 Global Long-acting Retinal Drugs Company, Product Type & Application
- 3.5 Global Long-acting Retinal Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Long-acting Retinal Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Long-acting Retinal Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Long-acting Retinal Drugs Tier 1, Tier 2, and Tier 3
4 Long-acting Retinal Drugs Market by Type
- 4.1 Global Long-acting Retinal Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Long-acting Retinal Drugs Market Size by Type (2021-2032)
- 4.3 Global Long-acting Retinal Drugs Market Size Share by Type (2021-2032)
5 Long-acting Retinal Drugs Market by Application
- 5.1 Global Long-acting Retinal Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Long-acting Retinal Drugs Market Size by Application (2021-2032)
- 5.3 Global Long-acting Retinal Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Janssen Pharmaceuticals (Johnson & Johnson)
- 6.1.1 Janssen Pharmaceuticals (Johnson & Johnson) Company Information
- 6.1.2 Janssen Pharmaceuticals (Johnson & Johnson) Business Overview
- 6.1.3 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio
- 6.1.5 Janssen Pharmaceuticals (Johnson & Johnson) Recent Developments
- 6.2 Takeda
- 6.2.1 Takeda Company Information
- 6.2.2 Takeda Business Overview
- 6.2.3 Takeda Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Takeda Long-acting Retinal Drugs Product Portfolio
- 6.2.5 Takeda Recent Developments
- 6.3 Teva Pharmaceutical
- 6.3.1 Teva Pharmaceutical Company Information
- 6.3.2 Teva Pharmaceutical Business Overview
- 6.3.3 Teva Pharmaceutical Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio
- 6.3.5 Teva Pharmaceutical Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Novartis Long-acting Retinal Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Merck
- 6.5.1 Merck Company Information
- 6.5.2 Merck Business Overview
- 6.5.3 Merck Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Merck Long-acting Retinal Drugs Product Portfolio
- 6.5.5 Merck Recent Developments
- 6.6 Bayer
- 6.6.1 Bayer Company Information
- 6.6.2 Bayer Business Overview
- 6.6.3 Bayer Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Bayer Long-acting Retinal Drugs Product Portfolio
- 6.6.5 Bayer Recent Developments
- 6.7 Alcon Inc.
- 6.7.1 Alcon Inc. Company Information
- 6.7.2 Alcon Inc. Business Overview
- 6.7.3 Alcon Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Alcon Inc. Long-acting Retinal Drugs Product Portfolio
- 6.7.5 Alcon Inc. Recent Developments
- 6.8 AbbVie Inc.
- 6.8.1 AbbVie Inc. Company Information
- 6.8.2 AbbVie Inc. Business Overview
- 6.8.3 AbbVie Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 AbbVie Inc. Long-acting Retinal Drugs Product Portfolio
- 6.8.5 AbbVie Inc. Recent Developments
- 6.9 ThromboGenics
- 6.9.1 ThromboGenics Company Information
- 6.9.2 ThromboGenics Business Overview
- 6.9.3 ThromboGenics Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 ThromboGenics Long-acting Retinal Drugs Product Portfolio
- 6.9.5 ThromboGenics Recent Developments
- 6.10 Regeneron
- 6.10.1 Regeneron Company Information
- 6.10.2 Regeneron Business Overview
- 6.10.3 Regeneron Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Regeneron Long-acting Retinal Drugs Product Portfolio
- 6.10.5 Regeneron Recent Developments
- 6.11 Oxurion NV
- 6.11.1 Oxurion NV Company Information
- 6.11.2 Oxurion NV Business Overview
- 6.11.3 Oxurion NV Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Oxurion NV Long-acting Retinal Drugs Product Portfolio
- 6.11.5 Oxurion NV Recent Developments
- 6.12 OncoGene Pharmaceuticals
- 6.12.1 OncoGene Pharmaceuticals Company Information
- 6.12.2 OncoGene Pharmaceuticals Business Overview
- 6.12.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio
- 6.12.5 OncoGene Pharmaceuticals Recent Developments
- 6.13 MeiraGTx Limited
- 6.13.1 MeiraGTx Limited Company Information
- 6.13.2 MeiraGTx Limited Business Overview
- 6.13.3 MeiraGTx Limited Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio
- 6.13.5 MeiraGTx Limited Recent Developments
- 6.14 F. Hoffmann-La Roche
- 6.14.1 F. Hoffmann-La Roche Company Information
- 6.14.2 F. Hoffmann-La Roche Business Overview
- 6.14.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio
- 6.14.5 F. Hoffmann-La Roche Recent Developments
- 6.15 Bausch Health Co. Inc.
- 6.15.1 Bausch Health Co. Inc. Company Information
- 6.15.2 Bausch Health Co. Inc. Business Overview
- 6.15.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio
- 6.15.5 Bausch Health Co. Inc. Recent Developments
- 6.16 Allergan
- 6.16.1 Allergan Company Information
- 6.16.2 Allergan Business Overview
- 6.16.3 Allergan Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Allergan Long-acting Retinal Drugs Product Portfolio
- 6.16.5 Allergan Recent Developments
- 6.17 Alimera Sciences Inc.
- 6.17.1 Alimera Sciences Inc. Company Information
- 6.17.2 Alimera Sciences Inc. Business Overview
- 6.17.3 Alimera Sciences Inc. Long-acting Retinal Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio
- 6.17.5 Alimera Sciences Inc. Recent Developments
7 North America
- 7.1 North America Long-acting Retinal Drugs Market Size (2021-2032)
- 7.2 North America Long-acting Retinal Drugs Market Size by Type
- 7.2.1 North America Long-acting Retinal Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Long-acting Retinal Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Long-acting Retinal Drugs Market Share by Type (2021-2032)
- 7.3 North America Long-acting Retinal Drugs Market Size by Application
- 7.3.1 North America Long-acting Retinal Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Long-acting Retinal Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Long-acting Retinal Drugs Market Share by Application (2021-2032)
- 7.4 North America Long-acting Retinal Drugs Market Size by Country
- 7.4.1 North America Long-acting Retinal Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Long-acting Retinal Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Long-acting Retinal Drugs Market Size (2021-2032)
- 8.2 Europe Long-acting Retinal Drugs Market Size by Type
- 8.2.1 Europe Long-acting Retinal Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Long-acting Retinal Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Long-acting Retinal Drugs Market Share by Type (2021-2032)
- 8.3 Europe Long-acting Retinal Drugs Market Size by Application
- 8.3.1 Europe Long-acting Retinal Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Long-acting Retinal Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Long-acting Retinal Drugs Market Share by Application (2021-2032)
- 8.4 Europe Long-acting Retinal Drugs Market Size by Country
- 8.4.1 Europe Long-acting Retinal Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Long-acting Retinal Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Long-acting Retinal Drugs Market Size (2021-2032)
- 9.2 China Long-acting Retinal Drugs Market Size by Type
- 9.2.1 China Long-acting Retinal Drugs Market Size by Type (2021-2026)
- 9.2.2 China Long-acting Retinal Drugs Market Size by Type (2027-2032)
- 9.2.3 China Long-acting Retinal Drugs Market Share by Type (2021-2032)
- 9.3 China Long-acting Retinal Drugs Market Size by Application
- 9.3.1 China Long-acting Retinal Drugs Market Size by Application (2021-2026)
- 9.3.2 China Long-acting Retinal Drugs Market Size by Application (2027-2032)
- 9.3.3 China Long-acting Retinal Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Long-acting Retinal Drugs Market Size (2021-2032)
- 10.2 Asia Long-acting Retinal Drugs Market Size by Type
- 10.2.1 Asia Long-acting Retinal Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Long-acting Retinal Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Long-acting Retinal Drugs Market Share by Type (2021-2032)
- 10.3 Asia Long-acting Retinal Drugs Market Size by Application
- 10.3.1 Asia Long-acting Retinal Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Long-acting Retinal Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Long-acting Retinal Drugs Market Share by Application (2021-2032)
- 10.4 Asia Long-acting Retinal Drugs Market Size by Country
- 10.4.1 Asia Long-acting Retinal Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Long-acting Retinal Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Long-acting Retinal Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Long-acting Retinal Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Long-acting Retinal Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Long-acting Retinal Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Long-acting Retinal Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst